​

Apellis Pharmaceuticals (APLS) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

APLS Stock Forecast

Apellis Pharmaceuticals (APLS) stock forecast, based on 25 Wall Street analysts, predicts a 12-month average price target of $24.00, with a high of $32.00 and a low of $18.00. This represents a -20.13% decline from the last price of $30.05.

$15 $25 $35 $45 $55 $65 High: $32 Avg: $24 Low: $18 Last Closed Price: $30.05

APLS Stock Rating

Apellis Pharmaceuticals stock's rating consensus is Buy, based on 25 Wall Street analysts. The breakdown includes 1 Strong Buy (4.00%), 17 Buy (68.00%), 6 Hold (24.00%), 1 Sell (4.00%), and 0 Strong Sell (0.00%).

Buy
Total 25 1 6 17 1 Strong Sell Sell Hold Buy Strong Buy

APLS Price Target Upside V Benchmarks

TypeNameUpside
StockApellis Pharmaceuticals-20.13%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts245
Avg Price Target$28.00$24.00$30.60
Last Closing Price$30.05$30.05$30.05
Upside/Downside-6.82%-20.13%1.83%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Oct, 254971-21
Sep, 25498--21
Aug, 25499--22
Jul, 25499--22
Jun, 254108--22
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 29, 2025Mizuho Securities$24.00$29.70-19.19%-20.13%
Oct 15, 2025Wells Fargo$32.00$23.1538.23%6.49%
Sep 26, 2025Goldman Sachs$18.00$21.85-17.62%-40.10%
Jul 30, 2025Scotiabank$22.00$19.0015.79%-26.79%
Nov 06, 2024Douglas TsaoH.C. Wainwright$57.00$27.01111.03%89.68%
Sep 23, 2024Colleen KusyRobert W. Baird$92.00$31.75189.76%206.16%
Sep 20, 2024Annabel SamimyStifel Nicolaus$84.00$31.68165.15%179.53%
Sep 20, 2024Graig SuvannavejhMizuho Securities$39.00$36.736.18%29.78%
Sep 16, 2024Graig SuvannavejhMizuho Securities$42.00$37.6211.64%39.77%
Aug 09, 2024Colleen KusyRobert W. Baird$96.00$37.66154.91%219.47%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Oct 21, 2025H.C. WainwrightBuyBuyhold
Oct 15, 2025Wells FargoSector PerformOverweightupgrade
Sep 26, 2025Goldman SachsBuySelldowngrade
Jul 30, 2025ScotiabankSector PerformSector Performhold
Jan 07, 2025RBC CapitalSector PerformSector Performhold
Nov 05, 2024Bank of America SecuritiesBuyBuyhold
Oct 16, 2024Wells FargoSector PerformSector Performhold
Oct 16, 2024William BlairOutperforminitialise
Sep 22, 2024CitigroupBuyBuyhold
Sep 13, 2024WedbushBuyBuyhold

Financial Forecast

EPS Forecast

$-15 $-9 $-3 $3 $9 $15 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-4.59$-8.84$-6.15$-4.45$-1.60----
Avg Forecast$-5.85$-8.70$-6.27$-4.48$-1.66$-0.90$0.63$1.08$2.37
High Forecast$-5.30$-7.89$-5.68$-3.86$-1.56$0.07$10.66$2.81$2.93
Low Forecast$-6.86$-10.21$-7.37$-5.06$-1.88$-1.45$-2.05$-0.10$1.99
Surprise %-21.54%1.61%-1.91%-0.67%-3.61%----

Revenue Forecast

$0 $400M $800M $1B $2B $2B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$250.65M$66.56M$75.42M$396.59M$709.95M----
Avg Forecast$98.49M$15.01M$76.64M$390.75M$766.78M$857.55M$1.08B$1.21B$1.46B
High Forecast$111.59M$17.00M$87.04M$396.54M$782.30M$1.02B$1.08B$1.22B$1.72B
Low Forecast$91.44M$13.93M$71.17M$386.55M$755.57M$777.37M$1.08B$1.21B$1.28B
Surprise %154.49%343.56%-1.59%1.49%-7.41%----

Net Income Forecast

$-1B $-500M $0 $500M $1B $2B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-344.87M$-746.35M$-652.17M$-528.63M$-197.88M----
Avg Forecast$-693.80M$-488.72M$-578.22M$-528.63M$-204.51M$-134.94M$-11.88M$156.49M$281.76M
High Forecast$-629.25M$-390.98M$-462.58M$-422.90M$-185.39M$7.85M$1.26B$333.91M$348.22M
Low Forecast$-813.79M$-586.47M$-693.87M$-634.35M$-223.62M$-171.76M$-242.72M$-12.24M$236.38M
Surprise %-50.29%52.71%12.79%--3.24%----

APLS Forecast FAQ

Is Apellis Pharmaceuticals stock a buy?

Apellis Pharmaceuticals stock has a consensus rating of Buy, based on 25 Wall Street analysts. The rating breakdown includes 1 Strong Buy, 17 Buy, 6 Hold, 1 Sell, and 0 Strong Sell, reflecting a consensus that Apellis Pharmaceuticals is a favorable investment for most analysts.

What is Apellis Pharmaceuticals's price target?

Apellis Pharmaceuticals's price target, set by 25 Wall Street analysts, averages $24 over the next 12 months. The price target range spans from $18 at the low end to $32 at the high end, suggesting a potential -20.13% change from the previous closing price of $30.05.

How does Apellis Pharmaceuticals stock forecast compare to its benchmarks?

Apellis Pharmaceuticals's stock forecast shows a -20.13% downside, underperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Apellis Pharmaceuticals over the past three months?

  • October 2025: 19.05% Strong Buy, 42.86% Buy, 33.33% Hold, 4.76% Sell, 0% Strong Sell.
  • September 2025: 19.05% Strong Buy, 42.86% Buy, 38.10% Hold, 0% Sell, 0% Strong Sell.
  • August 2025: 18.18% Strong Buy, 40.91% Buy, 40.91% Hold, 0% Sell, 0% Strong Sell.

What is Apellis Pharmaceuticals’s EPS forecast?

Apellis Pharmaceuticals's average annual EPS forecast for its fiscal year ending in December 2025 is $-0.9, marking a -43.75% decrease from the reported $-1.6 in 2024. Estimates for the following years are $0.63 in 2026, $1.08 in 2027, and $2.37 in 2028.

What is Apellis Pharmaceuticals’s revenue forecast?

Apellis Pharmaceuticals's average annual revenue forecast for its fiscal year ending in December 2025 is $857.55M, reflecting a 20.79% increase from the reported $709.95M in 2024. The forecast for 2026 is $1.08B, followed by $1.21B for 2027, and $1.46B for 2028.

What is Apellis Pharmaceuticals’s net income forecast?

Apellis Pharmaceuticals's net income forecast for the fiscal year ending in December 2025 stands at $-135M, representing a -31.80% decrease from the reported $-198M in 2024. Projections indicate $-11.883M in 2026, $156.49M in 2027, and $281.76M in 2028.